Literature DB >> 23219378

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

Fabio A B Schutz1, Mark M Pomerantz, Kathryn P Gray, Michael B Atkins, Jonathan E Rosenberg, Michelle S Hirsch, David F McDermott, Megan E Lampron, Gwo-Shu Mary Lee, Sabina Signoretti, Philip W Kantoff, Matthew L Freedman, Toni K Choueiri.   

Abstract

BACKGROUND: Germline genetic polymorphisms might affect the risk of recurrence in patients with localised renal-cell carcinoma. We investigated the association between genetic polymorphisms and recurrence of renal-cell carcinoma.
METHODS: We analysed germline DNA samples extracted from patients with localised renal-cell carcinoma treated at the Dana-Farber/Harvard Cancer Center (Boston, MA, USA). We selected a discovery cohort from a prospective database at the Dana-Farber/Harvard Cancer Center and selected a validation cohort from department records at the Brigham and Women's Hospital (Boston, MA, USA). We validated the findings from the discovery cohort in the validation cohort. We genotyped 70 genes involved in the pathogenesis of renal-cell carcinoma (including the VHL/HIF/VEGF and PI3K/AKT/mTOR pathways, and genes involved in immune regulation and metabolism) for single nucleotide polymorphisms. We assessed the association between genotype and recurrence-free survival, adjusted for baseline characteristics, with the Cox proportional hazards model, the Kaplan-Meier method, and the log-rank test. We used a false discovery rate q value to adjust for multiple comparisons.
FINDINGS: We included 554 patients (403 in the discovery cohort and 151 in the validation cohort). We successfully genotyped 290 single nucleotide polymorphisms in the discovery cohort, but excluded five because they did not have a variant group for comparison. The polymorphism rs11762213, which causes a synonymous aminoacid change in MET (144G→A, located in exon 2), was associated with recurrence-free survival. Patients with one or two copies of the minor (risk) allele had an increased risk of recurrence or death (hazard ratio [HR] 1·86, 95% CI 1·17-2·95; p=0·0084) in multivariate analysis. Median recurrence-free survival for carriers of the risk allele was 19 months (95% CI 9-not reached) versus 50 months (95% CI 37-75) for patients without the risk allele. In the validation cohort the HR was 2·45 (95% CI 1·01-5·95; p=0·048).
INTERPRETATION: Patients with localised renal-cell carcinoma and the MET polymorphism rs11762213 might have an increased risk of recurrence after nephrectomy. If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma. FUNDING: Conquer Cancer Foundation and American Society of Clinical Oncology (Career Development Award); The Trust Family Research Fund for Kidney Cancer; US National Institutes of Health, National Cancer Institute Kidney Cancer Specialized Program of Research Excellence.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219378      PMCID: PMC3769687          DOI: 10.1016/S1470-2045(12)70517-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  29 in total

Review 1.  Germline genetic variation, cancer outcome, and pharmacogenetics.

Authors:  Linda Coate; Sinead Cuffe; Anne Horgan; Rayjean J Hung; David Christiani; Geoffrey Liu
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Renal-cell carcinoma--molecular pathways and therapies.

Authors:  James Brugarolas
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

Authors:  Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

4.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

5.  Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.

Authors:  Mark M Pomerantz; Lillian Werner; Wanling Xie; Meredith M Regan; Gwo-Shu Mary Lee; Tong Sun; Carolyn Evan; Gillian Petrozziello; Mari Nakabayashi; William K Oh; Philip W Kantoff; Matthew L Freedman
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-02

Review 6.  New insights into the biology of renal cell carcinoma.

Authors:  Lianjie Li; William G Kaelin
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

7.  A second generation human haplotype map of over 3.1 million SNPs.

Authors:  Kelly A Frazer; Dennis G Ballinger; David R Cox; David A Hinds; Laura L Stuve; Richard A Gibbs; John W Belmont; Andrew Boudreau; Paul Hardenbol; Suzanne M Leal; Shiran Pasternak; David A Wheeler; Thomas D Willis; Fuli Yu; Huanming Yang; Changqing Zeng; Yang Gao; Haoran Hu; Weitao Hu; Chaohua Li; Wei Lin; Siqi Liu; Hao Pan; Xiaoli Tang; Jian Wang; Wei Wang; Jun Yu; Bo Zhang; Qingrun Zhang; Hongbin Zhao; Hui Zhao; Jun Zhou; Stacey B Gabriel; Rachel Barry; Brendan Blumenstiel; Amy Camargo; Matthew Defelice; Maura Faggart; Mary Goyette; Supriya Gupta; Jamie Moore; Huy Nguyen; Robert C Onofrio; Melissa Parkin; Jessica Roy; Erich Stahl; Ellen Winchester; Liuda Ziaugra; David Altshuler; Yan Shen; Zhijian Yao; Wei Huang; Xun Chu; Yungang He; Li Jin; Yangfan Liu; Yayun Shen; Weiwei Sun; Haifeng Wang; Yi Wang; Ying Wang; Xiaoyan Xiong; Liang Xu; Mary M Y Waye; Stephen K W Tsui; Hong Xue; J Tze-Fei Wong; Luana M Galver; Jian-Bing Fan; Kevin Gunderson; Sarah S Murray; Arnold R Oliphant; Mark S Chee; Alexandre Montpetit; Fanny Chagnon; Vincent Ferretti; Martin Leboeuf; Jean-François Olivier; Michael S Phillips; Stéphanie Roumy; Clémentine Sallée; Andrei Verner; Thomas J Hudson; Pui-Yan Kwok; Dongmei Cai; Daniel C Koboldt; Raymond D Miller; Ludmila Pawlikowska; Patricia Taillon-Miller; Ming Xiao; Lap-Chee Tsui; William Mak; You Qiang Song; Paul K H Tam; Yusuke Nakamura; Takahisa Kawaguchi; Takuya Kitamoto; Takashi Morizono; Atsushi Nagashima; Yozo Ohnishi; Akihiro Sekine; Toshihiro Tanaka; Tatsuhiko Tsunoda; Panos Deloukas; Christine P Bird; Marcos Delgado; Emmanouil T Dermitzakis; Rhian Gwilliam; Sarah Hunt; Jonathan Morrison; Don Powell; Barbara E Stranger; Pamela Whittaker; David R Bentley; Mark J Daly; Paul I W de Bakker; Jeff Barrett; Yves R Chretien; Julian Maller; Steve McCarroll; Nick Patterson; Itsik Pe'er; Alkes Price; Shaun Purcell; Daniel J Richter; Pardis Sabeti; Richa Saxena; Stephen F Schaffner; Pak C Sham; Patrick Varilly; David Altshuler; Lincoln D Stein; Lalitha Krishnan; Albert Vernon Smith; Marcela K Tello-Ruiz; Gudmundur A Thorisson; Aravinda Chakravarti; Peter E Chen; David J Cutler; Carl S Kashuk; Shin Lin; Gonçalo R Abecasis; Weihua Guan; Yun Li; Heather M Munro; Zhaohui Steve Qin; Daryl J Thomas; Gilean McVean; Adam Auton; Leonardo Bottolo; Niall Cardin; Susana Eyheramendy; Colin Freeman; Jonathan Marchini; Simon Myers; Chris Spencer; Matthew Stephens; Peter Donnelly; Lon R Cardon; Geraldine Clarke; David M Evans; Andrew P Morris; Bruce S Weir; Tatsuhiko Tsunoda; James C Mullikin; Stephen T Sherry; Michael Feolo; Andrew Skol; Houcan Zhang; Changqing Zeng; Hui Zhao; Ichiro Matsuda; Yoshimitsu Fukushima; Darryl R Macer; Eiko Suda; Charles N Rotimi; Clement A Adebamowo; Ike Ajayi; Toyin Aniagwu; Patricia A Marshall; Chibuzor Nkwodimmah; Charmaine D M Royal; Mark F Leppert; Missy Dixon; Andy Peiffer; Renzong Qiu; Alastair Kent; Kazuto Kato; Norio Niikawa; Isaac F Adewole; Bartha M Knoppers; Morris W Foster; Ellen Wright Clayton; Jessica Watkin; Richard A Gibbs; John W Belmont; Donna Muzny; Lynne Nazareth; Erica Sodergren; George M Weinstock; David A Wheeler; Imtaz Yakub; Stacey B Gabriel; Robert C Onofrio; Daniel J Richter; Liuda Ziaugra; Bruce W Birren; Mark J Daly; David Altshuler; Richard K Wilson; Lucinda L Fulton; Jane Rogers; John Burton; Nigel P Carter; Christopher M Clee; Mark Griffiths; Matthew C Jones; Kirsten McLay; Robert W Plumb; Mark T Ross; Sarah K Sims; David L Willey; Zhu Chen; Hua Han; Le Kang; Martin Godbout; John C Wallenburg; Paul L'Archevêque; Guy Bellemare; Koji Saeki; Hongguang Wang; Daochang An; Hongbo Fu; Qing Li; Zhen Wang; Renwu Wang; Arthur L Holden; Lisa D Brooks; Jean E McEwen; Mark S Guyer; Vivian Ota Wang; Jane L Peterson; Michael Shi; Jack Spiegel; Lawrence M Sung; Lynn F Zacharia; Francis S Collins; Karen Kennedy; Ruth Jamieson; John Stewart
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

Review 8.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

9.  Variants in blood pressure genes and the risk of renal cell carcinoma.

Authors:  Gabriella Andreotti; Paolo Boffetta; Philip S Rosenberg; Sonja I Berndt; Sara Karami; Idan Menashe; Meredith Yeager; Stephen J Chanock; David Zaridze; Vsevolod Matteev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Marie Navratilova; Neonilia Szeszenia-Dabrowska; Dana Mates; Nathaniel Rothman; Paul Brennan; Wong-Ho Chow; Lee E Moore
Journal:  Carcinogenesis       Date:  2010-01-04       Impact factor: 4.944

10.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3.

Authors:  Mark P Purdue; Mattias Johansson; Diana Zelenika; Jorge R Toro; Ghislaine Scelo; Lee E Moore; Egor Prokhortchouk; Xifeng Wu; Lambertus A Kiemeney; Valerie Gaborieau; Kevin B Jacobs; Wong-Ho Chow; David Zaridze; Vsevolod Matveev; Jan Lubinski; Joanna Trubicka; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Péter Rudnai; Eleonora Fabianova; Alexandru Bucur; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Paolo Boffetta; Joanne S Colt; Faith G Davis; Kendra L Schwartz; Rosamonde E Banks; Peter J Selby; Patricia Harnden; Christine D Berg; Ann W Hsing; Robert L Grubb; Heiner Boeing; Paolo Vineis; Françoise Clavel-Chapelon; Domenico Palli; Rosario Tumino; Vittorio Krogh; Salvatore Panico; Eric J Duell; José Ramón Quirós; Maria-José Sanchez; Carmen Navarro; Eva Ardanaz; Miren Dorronsoro; Kay-Tee Khaw; Naomi E Allen; H Bas Bueno-de-Mesquita; Petra H M Peeters; Dimitrios Trichopoulos; Jakob Linseisen; Börje Ljungberg; Kim Overvad; Anne Tjønneland; Isabelle Romieu; Elio Riboli; Anush Mukeria; Oxana Shangina; Victoria L Stevens; Michael J Thun; W Ryan Diver; Susan M Gapstur; Paul D Pharoah; Douglas F Easton; Demetrius Albanes; Stephanie J Weinstein; Jarmo Virtamo; Lars Vatten; Kristian Hveem; Inger Njølstad; Grethe S Tell; Camilla Stoltenberg; Rajiv Kumar; Kvetoslava Koppova; Olivier Cussenot; Simone Benhamou; Egbert Oosterwijk; Sita H Vermeulen; Katja K H Aben; Saskia L van der Marel; Yuanqing Ye; Christopher G Wood; Xia Pu; Alexander M Mazur; Eugenia S Boulygina; Nikolai N Chekanov; Mario Foglio; Doris Lechner; Ivo Gut; Simon Heath; Hélène Blanche; Amy Hutchinson; Gilles Thomas; Zhaoming Wang; Meredith Yeager; Joseph F Fraumeni; Konstantin G Skryabin; James D McKay; Nathaniel Rothman; Stephen J Chanock; Mark Lathrop; Paul Brennan
Journal:  Nat Genet       Date:  2010-12-05       Impact factor: 38.330

View more
  28 in total

1.  β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.

Authors:  Yidong Liu; Haiou Liu; Weisi Liu; Weijuan Zhang; Huimin An; Jiejie Xu
Journal:  World J Urol       Date:  2015-01-29       Impact factor: 4.226

Review 2.  c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Authors:  Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Kidney cancer: Recurrence in renal cell carcinoma: the work is not done.

Authors:  Maxine Sun; Toni K Choueiri
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

4.  Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.

Authors:  A Ari Hakimi; Irina Ostrovnaya; Boris Reva; Nikolaus Schultz; Ying-Bei Chen; Mithat Gonen; Han Liu; Shugaku Takeda; Martin H Voss; Satish K Tickoo; Victor E Reuter; Paul Russo; Emily H Cheng; Chris Sander; Robert J Motzer; James J Hsieh
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

Review 5.  Tumour and patient factors in renal cell carcinoma-towards personalized therapy.

Authors:  Ahmed Q Haddad; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

Review 6.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 7.  Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Authors:  Brandon J Manley; Abraham Ari Hakimi
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

8.  Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Authors:  Richard W Joseph; Payal Kapur; Daniel J Serie; Mansi Parasramka; Thai H Ho; John C Cheville; Eugene Frenkel; Alexander S Parker; James Brugarolas
Journal:  J Urol       Date:  2015-08-20       Impact factor: 7.450

9.  Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.

Authors:  Yu Sunakawa; Takeru Wakatsuki; Dongyun Yang; Wu Zhang; Yan Ning; Sebastian Stintzing; Stefan Stremitzer; Shinichi Yamauchi; Ana Sebio; Rita El-khoueiry; Syma Iqbal; Afsaneh Barzi; Armin Gerger; Michael Stotz; Mizutomo Azuma; Masahiko Watanabe; Wasaburo Koizumi; Heinz-Josef Lenz
Journal:  Pharmacogenet Genomics       Date:  2014-12       Impact factor: 2.089

10.  Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Irina Ostrovnaya; Anders Jacobsen; Katalin Susztak; Jonathan A Coleman; Paul Russo; Andrew G Winer; Roy Mano; Alexander I Sankin; Robert J Motzer; Martin H Voss; Kenneth Offit; Mark Purdue; Mark Pomerantz; Matthew Freedman; Toni K Choueiri; James J Hsieh; Robert J Klein
Journal:  Cancer       Date:  2015-10-27       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.